The First Affiliated Hospital with Nanjing Medical University
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China32 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial | Cirrhosis, Familial, with Pulmonary Hypertension, Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2026-10-09 | NCT07847710 | |
| Heart Rate Variability Changes and Postoperative Delirium After Major Abdominal Surgery | Confusion, Emergence Delirium, Neurobehavioral Manifestations, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Signs and Symptoms, cognitive disorder, delirium, nervous system disorder, psychiatric disorder | Recruiting | Not stated | 2026-09-28 | NCT07783464 | |
| RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies | autoimmune disease, immune system disorder | Recruiting | Phase 1 | 2026-09-01 | NCT07105735 | |
| VA Dual Sequential Therapy | Helicobacter Pylori Infection | Recruiting | Phase 4 | 2026-09-01 | NCT06929962 | |
| Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors | Selected Types of Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-08-04 | NCT07095868 | |
| Study on the Thrombolytic Effect of Platelet Membrane Coated Tenecteplase on Human Arterial Thrombus | Arterial Thrombosis | Recruiting | Not stated | 2026-07-17 | NCT07712445 | |
| Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not applicable | 2026-07-14 | NCT06577792 | |
| Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL | diffuse large B-cell lymphoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-06-12 | NCT07643805 | |
| Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Early phase 1 | 2026-06-10 | NCT07628595 | |
| A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Not yet recruiting | Phase 1 | 2026-06-05 | NCT07628582 | |
| The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 1 | 2026-05-14 | NCT07002112 | |
| CSP Versus BiVP for Heart Failure Patients With RVP Upgraded to Cardiac Resynchronization Therapy | cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2026-05-14 | NCT06241651 | |
| A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD | cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2026-05-14 | NCT06061627 | |
| LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB | Arrhythmias, Cardiac, Cardiac Conduction System Disease, Left Bundle-Branch Block, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrioventricular dissociation, cardiovascular disorder, heart disorder, heart failure, progressive familial heart block, type 1A | Active, not recruiting | Not applicable | 2026-05-14 | NCT05572957 | |
| Protection of Cardiac Function With Left Bundle Branch Pacing in Patients With Atrioventricular Block | Arrhythmias, Cardiac, Cardiac Conduction System Disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrioventricular block, atrioventricular dissociation, cardiovascular disorder, heart disorder | Active, not recruiting | Not applicable | 2026-05-14 | NCT04624763 | |
| 7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy | Helicobacter Pylori | Recruiting | Phase 4 | 2026-04-08 | NCT07232095 | |
| Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-03-04 | NCT07448324 | |
| Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-02-18 | NCT07418177 | |
| PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. | Primary Central Nervous System Lymphoma (PCNSL); Secondary Central Nervous System Lymphoma (SCNSL) | Recruiting | Phase 2 | 2026-02-13 | NCT07410520 | |
| A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer | gastric adenocarcinoma | Recruiting | Phase 2 | 2025-12-04 | NCT07263386 | |
| Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Not yet recruiting | Phase 4 | 2025-10-01 | NCT07200336 | |
| Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 2 | 2025-09-29 | NCT07195799 | |
| Interventional Treatment of Chronic Tinnitus With Acoustic Stimulation | Chronic Tinnitus | Recruiting | Not applicable | 2025-09-22 | NCT07185061 | |
| A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm, type 1 diabetes mellitus 12 | Not yet recruiting | Phase 2 | 2025-08-20 | NCT07131501 | |
| RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies | B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Tumor Virus Infections, cardiovascular disorder, diffuse large B-cell lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, plasmablastic lymphoma, vascular disorder, vascular hemostatic disease, viral infectious disease | Not yet recruiting | Phase 1 | 2025-08-13 | NCT07113496 |